Beam Therapeutics ( (BEAM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Beam Therapeutics’ stock saw a notable uptick following a series of positive developments. The FDA’s clearance of their investigational new drug application for BEAM-302, targeting the rare genetic disorder alpha-1 antitrypsin deficiency, played a pivotal role. This promising advancement, coupled with a Buy rating upgrade from BofA and a significant share purchase by Cathie Wood’s ARK Investment, bolstered investor confidence and led to a positive revaluation of the stock.
More about Beam Therapeutics
YTD Price Performance: -10.16%
Average Trading Volume: 1,609,039
Technical Sentiment Signal: Buy
Current Market Cap: $2.22B
For further insights into BEAM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.